Daiichi Sankyo Co Ltd 2010 SR
The report outlines the Daiichi Sankyo Group's CSR activities for fiscal 2009, focusing on its new Mid-term CSR Policy and five key goals: global compliance, diversity, stakeholder communication, environmental burden reduction, and global access to medicine. Key highlights include the integration of Ranbaxy Laboratories, achieving zero waste emissions in Japan, and reducing CO2 emissions by 9.5% compared to fiscal 2007. The company also emphasizes its Hybrid Business Model to provide innovative and generic pharmaceuticals globally.
Company: Daiichi Sankyo Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2010
Type: SR
Pages: 70
Back to company
Daiichi Sankyo Co Ltd
Corporate Social Responsibility Report
The report outlines the Daiichi Sankyo Group's CSR activities for fiscal 2009, focusing on its new Mid-term CSR Policy and five key goals: global compliance, diversity, stakeholder communication, environmental burden reduction, and global access to medicine. Key highlights include the integration of Ranbaxy Laboratories, achieving zero waste emissions in Japan, and reducing CO2 emissions by 9.5% compared to fiscal 2007. The company also emphasizes its Hybrid Business Model to provide innovative and generic pharmaceuticals globally.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2010
Reporting Period
Apr 1, 2009 - Mar 31, 2010
Fiscal Year
2009
Published
Sep 1, 2010
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women in Management
Employees